Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development of compounds active in insomnia: recent developments and methodological aspects].

L Staner1, R Luthringer, J-P Macher

  • 1Unité d'Exploration des Rythmes Veille-Sommeil et FORENAP, Centre Hospitalier de Rouffach, 27, rue du 4e RSM, 68250 Rouffach. luc.staner@forenap.asso.fr

Revue Neurologique
|December 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suicidal behavior in schizophrenia and family history of suicide.

Dialogues in clinical neuroscience·2011
Same author

Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge.

Journal of psychopharmacology (Oxford, England)·2009
Same author

Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.

Sleep medicine·2008
Same author

Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.

Human psychopharmacology·2008
Same author

Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers.

Neuropsychobiology·2007
Same author

Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.

Psychopharmacology·2007

New insomnia treatments aim for specific pathways, not global brain activity, to improve efficacy. Objective measures like polysomnography and EEG spectral analysis are crucial for evaluating drug effects and sleep quality.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Sleep Medicine

Context:

  • Current insomnia pharmacotherapies broadly target GABAergic systems.
  • This broad action may limit treatment efficacy and patient acceptance.
  • There is a need for more targeted therapeutic approaches.

Purpose:

  • To explore the development of novel molecules with specific activity pathways for insomnia.
  • To outline essential criteria for evaluating hypnotic drug efficacy and tolerability.
  • To emphasize the importance of objective sleep assessment methods.

Summary:

  • Investigates developing insomnia pharmacotherapies with targeted mechanisms beyond global GABAergic activity.
  • Highlights the necessity of both subjective and objective measures, including polysomnography and EEG spectral analysis, for efficacy assessment.

Related Experiment Videos

  • Discusses evaluating residual effects using psychomotor, neurocognitive, and driving simulator tests in carefully selected patient cohorts.

    • Impact:

    • Aims to improve treatment efficacy and acceptance for insomnia.
    • Establishes a framework for rigorous clinical evaluation of new hypnotic agents.
    • Contributes to advancing the understanding and treatment of insomnia through scientific rigor.